RPCI and University of Pittsburgh Cancer Institute experts discuss the significance of the SPORE in Ovarian Cancer award from the National Cancer Institute.

RPCI-UPCI Ovarian Cancer SPORE

Wednesday, October 16, 2013 - 11:11am

Roswell Park Cancer Institute (RPCI) and the University of Pittsburgh Cancer Institute (UPCI) were recently awarded an $11 million Ovarian Cancer Specialized Program of Research Excellence (SPORE) grant. These grants support innovative, multidisciplinary translational research projects and are awarded to leading centers that exhibit excellence in research, specifically research with a clear potential to improve and impact patient care and prevention.

The research team, led by Kunle Odunsi, MD, PhD, Principal Investigator of the RPCI/UPCI Ovarian Cancer SPORE grant, will study novel immunotherapy approaches for the treatment of and risk assessment for ovarian cancer. The research itself will encompass four projects: three clinical trials evaluating newly developed immunotherapies and one epidemiological study looking for ways to reduce risk in women at high risk of developing ovarian cancer.

The Ovarian Cancer SPORE Co-Principal Investigators include Kirsten B. Moysich, PhD, Professor in the Department of Immunology and Professor of Oncology in the Department of Cancer Prevention and Control at Roswell Park, and Robert P. Edwards, MD, executive Vice Chair of Gynecologic Services and Director of the Ovarian Cancer Center for Excellence, Gynecologic Program at Magee-Womens Hospital of the University of Pittsburgh Medical Center (UPMC).

To learn more about this SPORE award, visit: www.roswellpark.edu/spore or call 1-877-ASK-RPCI (1-877 275-7724).